Alternate pembrolizumab dosing interval in advanced NSCLC with PD-L1 >/[ 50%: 3 weekly compared to 6 weekly dosing L. Jones,R. Rittberg,B. Leung,A. Shokoohi,A. Pender,S. Wong,Z. S. Al-Hashami,Y. Wang,C. HoANNALS OF ONCOLOGY(2022)引用 0|浏览29暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要